AutoLoc: Autonomous Sensor Location Configuration Cross Modal Sensing.

Internet-of-Things (IoT) systems have become pervasive for smart homes. In recent years, many of these IoT sensing systems are developed to enable in-home long-term monitoring applications, such as personalized services in smart homes, elderly/patient monitoring, etc. However, these systems often require complicated and expensive installation processes, which are some of the main concerns affecting users' adoption of smart home systems.

Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.

Tacrolimus has proven to be a potent immunosuppressive agent in liver transplantation (LT). Its introduction has led to significantly less frequent and severe acute rejection. Little is known about the rate of chronic rejection (CR) in primary LT using tacrolimus therapy.

Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus.

Background: Tacrolimus is a potent immunosuppressive agent that provides higher freedom from acute and chronic rejection than cyclosporine after liver transplantation (LTx). Initially, a steroid-free state was observed in about 70% of patients at 1 year; this did not change over the next 5 years. The present study identifies the various reasons why the remaining 30% of adult patients still require steroids even after 5 years after successful LTx.

Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus.

Background: Liver transplantation (LTx) for alcohol-related liver disease (ALD) is an accepted modality of treatment and is one of the most common indications for LTx in the United States. The present report examines the long-term patient survival, graft survival, rates of recidivism, and development of de novo cancers in this group, and compares these results with a contemporaneous group of patients who were transplanted for non-ALD indications.

Methods: Between August 1989 and December 1992, 185 adults received LTx for ALD (group I).